Dividend Harvesting Portfolio Week 149: $14,900 Allocated, $1,316.50 In Projected DividendsSeeking Alpha • 01/11/24
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchSeeking Alpha • 01/10/24
Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader MarketZacks Investment Research • 01/10/24
Bristol-Myers CEO talks new acquisitions: 'We are writing the next chapter of this company'CNBC • 01/09/24
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript)Seeking Alpha • 01/04/24
Bristol-Myers Squibb downgraded on mixed sales performance of new products amid loss of exclusivity concernsProactive Investors • 01/03/24
European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid TumorsBusiness Wire • 01/02/24
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZBBusiness Wire • 12/31/23